Patent application number | Description | Published |
20090281144 | Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors - Bis-quaternary pyridinium-aldoxime salts are disclosed, and their associated polymorphic character, along with their methods of preparation. Such polymorphic salts may then be used for treatment of exposure to cholinesterase inhibitors, such as a phosphorous containing cholinesterase inhibitor type compound. | 11-12-2009 |
20100040692 | TWO PHASE BIOACTIVE FORMULATIONS - The present invention relates to two-phase systems of a bioactive ingredient in particle form that has limited or no solubility in a liquid medium, which provides stability to the active ingredient that is similar to the active ingredient when in the solid state. The active ingredient may be capable of therapeutically treating for the presence of a cholinesterase inhibitor. | 02-18-2010 |
20100086601 | Modified Calcium Phosphate Nanoparticle Formation - The present disclosure relates to non-aggregating nanoparticles and their associated methods of preparation. The nanoparticles may have a surface and a size range of 1 nm to 999 nm, along with a zeta potential of −50 to 50 millivolts. A polycation and/or polyanion may be disposed on the nanoparticle surface. In addition, an active ingredient may be encapsulated within the nanoparticles or associated with the polycation or polyanion on the nanoparticle surface. | 04-08-2010 |
20100098754 | PROCESSING OF HEAT-SENSITIVE ACTIVE AGENTS - The present disclosure relates to a method of melt processing an active agent. The method may include encapsulating an active agent in a first polymer material exhibiting a first processing temperature T | 04-22-2010 |
20110015568 | Dry To Wet Injector - The present disclosure relates to an apparatus and method for combining a solid particulate with a solvent prior to an injection protocol within an injector device. The solid particulate may be a pharmaceutical compound and the microcapsules contain a solvent for such particulate. Upon application of pressure, the microcapsules may be configured to burst and release the solvent, thereby dispersing and/or partially dissolving the particulate. The injector therefore allows for the use of relatively unstable pharmaceutically active compounds in a device that requires relatively long storage times and the use of pharmaceutical compounds that are relatively stable in the dry state. | 01-20-2011 |
20110195125 | Nanoparticles For Drug Delivery To The Central Nervous System - The present disclosure relates to compositions and methods for producing nanoparticles to provide relatively more rapid delivery of such particles across the blood-brain barrier. The nanoparticles may be formed from bis-quaternary pyridinium-aldoxime salts that may also be of a specific polymorphic structure and which may be formed in either hydrophobic or hydrophilic type liquid media. In addition, the nanoparticle for transport across the blood-brain barrier may comprise a polymeric resin encapsulating a bis-quaternary pyridinium-2-aldoxime salt of the formula: | 08-11-2011 |
20120070503 | Nanoparticle-Based Targeted Drug Delivery For In Vivo Bone Loss Mitigation - The present invention is directed to nanoparticle-based targeted drug delivery system for treatment of bone-loss. An enantiomeric phenothiazine is formulated into an in-vivo nanoparticle delivery system which may contain bone-targeting functionality. The nanoparticle formulations and their associated influence on whole bone porosity may now also be evaluated utilizing nuclear magnetic resonance (NMR) and relaxation time profiles, and in particular, median T | 03-22-2012 |
20130164381 | Nanoparticle-Based Targeted Drug Delivery For In Vivo Bone Loss Mitigation - The present invention is directed to nanoparticle-based targeted drug delivery system for treatment of bone-loss. An enantiomeric phenothiazine is formulated into an in-vivo nanoparticle delivery system which may contain bone-targeting functionality. The nanoparticle formulations and their associated influence on whole bone porosity may now also be evaluated utilizing nuclear magnetic resonance (NMR) and relaxation time profiles, and in particular, median T | 06-27-2013 |